[Telemedicine monitoring for AMD patients]. / Suivi en télémédecine des patients atteints de DMLA.

INTRODUCTION: AMD follow-up is a public health issue in developed countries due to aging of the population and medical demographics. Telemedicine may be a means of improving follow-up. PURPOSE: To compare the agreement between telemedicine and in-person consultations in terms of indications for intravitreal injections in exudative AMD patients. MATERIALS AND METHODS: From January 2017 to April 2017, AMD patients followed on a PRN protocol at a single center, Rennes university medical center, were included. The telemedicine evaluation was read by two anonymous experts on the basis of the medical record including visual acuity and fundus photographs. The agreement between conventional follow-up and telemedicine in terms of indications for intravitreal injections, as well as interobserver agreement, were tested with the Cohen's kappa coefficient using SAS statistical software V9.4 (SAS Institute, Cary, NC). RESULTS: In total, 104 eyes corresponding to 57 consultations for 42 patients were analyzed. The mean age was 82.12 years (standard deviation±6.4). Recommendations for anti-VEGF were similar between the standard and telemedicine visits in 97 % of cases. The Kappa coefficient was 0.8861 [0.76; 1.00], P<0.0001 for agreement between telemedicine and in-person consultation. The Kappa coefficient was 0.8441 [0.70; 0.99], P<0.0001 for interobserver agreement. We observed 5 cases of disagreement between the two observers. DISCUSSION: The concordance was very good in our study. The few cases of disagreement resulted mainly from poorly interpretable examinations due to poor image quality, major macular changes in patients with a prior examination, and the fact that only a single cut was analyzed. CONCLUSION: AMD monitoring by telemedicine seems promising and reliable. This approach would allow better follow-up of patients with difficult access to care.

[Application of gene therapy to oncologic ophthalmology]. / Application de la thérapie génique à l'onco-ophtalmologie.

Since the discovery of the structure of DNA in 1953 by Watson and Crick, our understanding of the genetic causes and the regulations involved in tumor development have hugely increased. The important amount of research developed since then has led to the development of gene therapy, which specifically targets and treats cancer cells by interacting with, and correcting their genetic material. This study is a review of the most accomplished research using gene therapy aimed at treating malignant ophthalmologic diseases, and focuses more specifically on uveal melanoma and retinoblastoma. Such approaches are remarkable regarding the efficiency and the cellular targeting specificity. However, gene therapy-based treatments are so recent that many long-term interrogations subsist. The majority of the reviewed studies are conducted in vitro or in murine models, thereby requiring several years before the resulting therapies become part of the daily ophthalmologists' arsenal. However, the recent spectacular developments based on advanced scientific knowledge justify an up-to-date review that would benefit the ophthalmologist community.